OTCMKTS:RCDTF Recordati Industria Chimica E Farmaceutica (RCDTF) Stock Price, News & Analysis $58.79 0.00 (0.00%) As of 10/8/2026 Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartEarningsNews and TrendsShort Interest About Recordati Industria Chimica E Farmaceutica Stock (OTCMKTS:RCDTF) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get RCDTF alerts:Sign Up Key Stats Today's Range$58.79▼$58.7950-Day Range$58.00▼$58.7952-Week Range$55.88▼$60.00VolumeN/AAverage Volume69 shsMarket Capitalization$12.13 billionP/E Ratio20.97Dividend YieldN/APrice TargetN/AConsensus RatingBuy Company Overview Recordati Industria Chimica e Farmaceutica S.p.A. is an Italian pharmaceutical company focused on the research, development, manufacture and commercialization of medicines. Its activities are centered on specialty-care and rare-disease treatments, with products addressing areas such as endocrinology, oncology, urology, cardiology, gastroenterology and other specialized medical needs. The company markets both proprietary and licensed medicines, serving patients through prescription products and therapies for uncommon or underserved conditions. Its rare-disease portfolio includes treatments for certain endocrine disorders and oncology-related conditions, while its broader specialty-care operations include established medicines distributed through its commercial organization and selected partnerships. Founded in Milan in 1926, Recordati has expanded from an Italian pharmaceutical business into an international company. It serves markets across Europe and in other regions, including selected countries in the Middle East, North Africa, Turkey and the United States. The company operates through research, manufacturing and commercial activities supported by a network of subsidiaries and partners.AI Generated. May Contain Errors. Read More Recordati Industria Chimica E Farmaceutica Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks12th Percentile Overall ScoreRCDTF MarketRank™: Recordati Industria Chimica E Farmaceutica scored higher than 12% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.5 / 5Analyst RatingBuy Consensus RatingRecordati Industria Chimica E Farmaceutica has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 strong buy rating, no buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageRecordati Industria Chimica E Farmaceutica has received no research coverage in the past 90 days.Read more about Recordati Industria Chimica E Farmaceutica's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Recordati Industria Chimica E Farmaceutica is 20.97, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.97.Price to Earnings Ratio vs. SectorThe P/E ratio of Recordati Industria Chimica E Farmaceutica is 20.97, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 274.63.Read more about Recordati Industria Chimica E Farmaceutica's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted0.03% of the float of Recordati Industria Chimica E Farmaceutica has been sold short.Short Interest Ratio / Days to CoverRecordati Industria Chimica E Farmaceutica has a short interest ratio ("days to cover") of 999.99, which indicates bearish sentiment.Change versus previous monthShort interest in Recordati Industria Chimica E Farmaceutica has recently increased by 32.07%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldRecordati Industria Chimica E Farmaceutica does not currently pay a dividend.Dividend GrowthRecordati Industria Chimica E Farmaceutica does not have a long track record of dividend growth. News and Social Media0.0 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Recordati Industria Chimica E Farmaceutica this week, compared to 0 articles on an average week. Company OwnershipN/AInsider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Recordati Industria Chimica E Farmaceutica insiders have not sold or bought any company stock.Percentage Held by InstitutionsRecordati Industria Chimica E Farmaceutica has minimal institutional ownership at this time.Read more about Recordati Industria Chimica E Farmaceutica's insider trading history. Receive RCDTF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Recordati Industria Chimica E Farmaceutica and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RCDTF Stock News HeadlinesHead to Head Comparison: Orion OYJ (OTCMKTS:ORINY) vs. Recordati Industria Chimica E Farmaceutica (OTCMKTS:RCDTF)October 4, 2026 | americanbankingnews.comIl piccolo azionista deve sapere queste cose prima dell'OPA di Recordati del 31 agostoAugust 26, 2026 | msn.comSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from collapsing — and billionaire Sam Altman is now an investor. This under-the-radar firm is drawing serious attention from those watching the energy infrastructure space closely.October 9 at 1:00 AM | Altimetry (Ad)Recordati, il cda approva l’opas: “Nessun rilancio, prezzo congruo”. Ma gli indipendenti dicono noJuly 16, 2026 | msn.comRecordati, il cda si spacca sull'opa. Gli indipendenti bocciano il prezzo, via libera con sei voti su dieciJuly 16, 2026 | msn.comCVC, GBL launch €10.7 billion bid for Italian drugmaker RecordatiMay 22, 2026 | reuters.comRecordati SpA (RCDTF) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and R&D ...May 15, 2026 | uk.finance.yahoo.comRECORDATI: STRONG MOMENTUM OF THE GROUP CONTINUES INTO THE FIRST QUARTER OF 2026 NET REVENUE +4.9%, EBITDA(1) +5.0%, ADJUSTED NET INCOME(2) +7.2%May 12, 2026 | markets.businessinsider.comSee More Headlines RCDTF Stock Analysis - Frequently Asked Questions How have RCDTF shares performed this year? Recordati Industria Chimica E Farmaceutica's stock was trading at $65.44 on January 1st, 2026. Since then, RCDTF shares have decreased by 10.2% and is now trading at $58.79. How were Recordati Industria Chimica E Farmaceutica's earnings last quarter? Recordati Industria Chimica E Farmaceutica S.P.A. (OTCMKTS:RCDTF) released its earnings results on Wednesday, July, 29th. The company reported $0.91 earnings per share for the quarter. The business earned $810.70 million during the quarter. Recordati Industria Chimica E Farmaceutica had a trailing twelve-month return on equity of 33.73% and a net margin of 18.38%. How do I buy shares of Recordati Industria Chimica E Farmaceutica? Shares of RCDTF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings7/29/2026Today10/09/2026Next Earnings (Estimated)11/10/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolOTCMKTS:RCDTF Previous SymbolNASDAQ:RCDTF CIKN/A Webwww.recordati.com Phone390-248-7871Fax39-02-4007-3747Employees4,693Year Founded1926Profitability EPS (Trailing Twelve Months)$2.80 Trailing P/E Ratio20.97 Forward P/E RatioN/A P/E GrowthN/ANet Income$501.92 million Net Margins18.38% Pretax MarginN/A Return on Equity33.73% Return on Assets12.76% Debt Debt-to-Equity Ratio0.79 Current Ratio1.26 Quick Ratio0.86 Sales & Book Value Annual Sales$2.96 billion Price / Sales4.10 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares206,300,000Free FloatN/AMarket Cap$12.13 billion OptionableNot Optionable Beta0.26 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (OTCMKTS:RCDTF) was last updated on 10/9/2026 by MarketBeat.com Staff. From Our PartnersThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Recordati Industria Chimica E Farmaceutica S.P.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Recordati Industria Chimica E Farmaceutica With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.